27 mars 2018 - FDA held a meeting of the Psychopharmacologic Drugs Advisory Committee to discuss the new drug application for lofexidine hydrochloride, submitted by US WorldMeds, LLC, for mitigation of symptoms associated with opioid withdrawal and facilitation of completion of opioid discontinuation treatment.
Ajouté au bande de temps:
Date:
27 mars 2018
Maintenaint
~ Il y a 7 ans et 7 mois